Latest Antiandrogens Stories
Ariad Pharmaceuticals has reported encouraging preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer.
Cougar Biotechnology, Inc.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today presented preclinical data on the investigational mTOR inhibitor, deforolimus, alone or in combination with the anti-androgen agent, bicalutamide, in models of prostate cancer.
Ariad Pharmaceuticals, a developer of medicines to treat cancer, has announced the initiation of a Phase II clinical trial by Merck & Co to evaluate the safety and efficacy of oral deforolimus, Ariad's investigational mTOR inhibitor, in patients with advanced prostate cancer.
Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that results from an ongoing Phase II clinical trial of Cougar's investigational drug CB7630 (abiraterone acetate) were presented today at the Prostate Cancer Foundation Scientific Retreat.
By Marie Price A new law requiring women to undergo an ultrasound before getting an abortion has been challenged in a lawsuit filed in Oklahoma County District Court by the Center for Reproductive Rights on behalf of Nova Health Systems, which does business as Reproductive Services in Tulsa.
US-based healthcare company AstraZeneca has announced that the FDA has granted an additional six-month period of exclusivity to market Casodex for its licensed advanced prostate cancer indication until April 1, 2009.
Men with locally advanced prostate cancer will survive substantially longer when radiation is added to their treatment plan, Swedish researchers said. Lead author Dr.
WILMINGTON, Del., Sept.
Some drugs given to men to help treat prostate cancer may actually spur some cancer cells to grow, U.S. researchers said.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.